ID

21413

Beskrivning

Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00511069

Länk

https://clinicaltrials.gov/show/NCT00511069

Nyckelord

Versioner (1)
  1. 2017-04-20 2017-04-20 -
Uppladdad den

20 april 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Leukemia NCT00511069

Engelsk

Eligibility Leukemia NCT00511069

1 Formulär  
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00511069
Criteria
Beskrivning

Criteria

1. age >/=18 years
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
2. ph positive
Beskrivning

Philadelphia positive

Datatyp

boolean

Alias
UMLS CUI [1]
C0457340
3. absence of a chr after 3 months on imatinib
Beskrivning

imatinib | Complete Hematologic Response Absent

Datatyp

boolean

Alias
UMLS CUI [1]
C0935989
UMLS CUI [2,1]
C4050175
UMLS CUI [2,2]
C0332197
4. loss of a previously obtained chr on imatinib alone
Beskrivning

imatinib | Complete Hematologic Response Obtained Previous | Complete Hematologic Response Lost

Datatyp

boolean

Alias
UMLS CUI [1]
C0935989
UMLS CUI [2,1]
C4050175
UMLS CUI [2,2]
C1301820
UMLS CUI [2,3]
C0205156
UMLS CUI [3,1]
C4050175
UMLS CUI [3,2]
C0745777
5. absence of a ccgr within 12 months on imatinib alone
Beskrivning

imatinib | Cytogenetic Complete Response Absent

Datatyp

boolean

Alias
UMLS CUI [1]
C0935989
UMLS CUI [2,1]
C4050364
UMLS CUI [2,2]
C0332197
6. loss of a previously obtained ccgr on imatinib alone
Beskrivning

imatinib | Cytogenetic Complete Response Obtained Previous | Cytogenetic Complete Response Lost

Datatyp

boolean

Alias
UMLS CUI [1]
C0935989
UMLS CUI [2,1]
C4050364
UMLS CUI [2,2]
C1301820
UMLS CUI [2,3]
C0205156
UMLS CUI [3,1]
C4050364
UMLS CUI [3,2]
C0745777
7. written informed consent
Beskrivning

Informed Consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
exclusion criteria for chronic phase patients :
Beskrivning

Exclusion Criteria | Chronic phase

Datatyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0457343
1. age <18
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
2. performance status (ecog/who) > 2 (see appendix 2)
Beskrivning

ECOG performance status | WHO performance status scale

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
UMLS CUI [2]
C1298650
3. inability to provide written informed consent
Beskrivning

Informed Consent Unable

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
4. pregnancy
Beskrivning

Pregnancy

Datatyp

boolean

Alias
UMLS CUI [1]
C0032961
5. accelerated or blastic phase
Beskrivning

Accelerated phase | Blastic Phase

Datatyp

boolean

Alias
UMLS CUI [1]
C0457345
UMLS CUI [2]
C3899938
6. formal refusal of any recommendation of a safe contraception
Beskrivning

Contraceptive methods Refused

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0700589
UMLS CUI [1,2]
C1705116
7. alcohol or drug addiction
Beskrivning

Substance Dependence

Datatyp

boolean

Alias
UMLS CUI [1]
C0038580
8. altered hepatic or renal function as defined by ast/alt or bilirubin > 3 times upper normal limits (unl)
Beskrivning

Liver function altered | Renal function altered | Aspartate aminotransferase increased | Alanine aminotransferase increased | Elevated total bilirubin

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0392747
UMLS CUI [2,1]
C0232804
UMLS CUI [2,2]
C0392747
UMLS CUI [3]
C0151904
UMLS CUI [4]
C0151905
UMLS CUI [5]
C0741494
9. serum creatinine > 265 umol/l or >3.0 mg/dl
Beskrivning

Creatinine measurement, serum

Datatyp

boolean

Alias
UMLS CUI [1]
C0201976
10. any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.
Beskrivning

Disease At risk Patient | Condition At risk Patient | Disease Study Subject Participation Status Ineligibility | Condition Study Subject Participation Status Ineligibility

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0030705
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C1444641
UMLS CUI [2,3]
C0030705
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C2348568
UMLS CUI [3,3]
C1512714
UMLS CUI [4,1]
C0348080
UMLS CUI [4,2]
C2348568
UMLS CUI [4,3]
C1512714
inclusion criteria for accelerated and blastic phase or acute lymphoblastic leukemia ph+
Beskrivning

Inclusion criteria | Accelerated phase | Blastic Phase | Philadelphia chromosome-positive acute lymphoblastic leukemia

Datatyp

boolean

Alias
UMLS CUI [1]
C1512693
UMLS CUI [2]
C0457345
UMLS CUI [3]
C3899938
UMLS CUI [4]
C1960397
patients:
Beskrivning

Patients

Datatyp

boolean

Alias
UMLS CUI [1]
C0030705
1. age >/=18 years
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
2. ph positive
Beskrivning

Philadelphia positive

Datatyp

boolean

Alias
UMLS CUI [1]
C0457340
3. loss of a previous hematological response to imatinib alone, with further progression to abp (see section 14 for definitions)
Beskrivning

imatinib | Hematologic Response Previous | Hematologic Response Lost | Progression Accelerated phase | Progression Blastic Phase

Datatyp

boolean

Alias
UMLS CUI [1]
C0935989
UMLS CUI [2,1]
C4054793
UMLS CUI [2,2]
C0205156
UMLS CUI [3,1]
C4054793
UMLS CUI [3,2]
C0745777
UMLS CUI [4,1]
C0449258
UMLS CUI [4,2]
C0457345
UMLS CUI [5,1]
C0449258
UMLS CUI [5,2]
C3899938
4. performance status (ecog/who)
Beskrivning

ECOG performance status | WHO performance status scale

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
UMLS CUI [2]
C1298650
5. written informed consent
Beskrivning

Informed Consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
exclusion criteria for accelerated and blastic phase or acute lymphoblastic leukemia ph+
Beskrivning

Exclusion Criteria | Accelerated phase | Blastic Phase | Philadelphia chromosome-positive acute lymphoblastic leukemia

Datatyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0457345
UMLS CUI [3]
C3899938
UMLS CUI [4]
C1960397
patients:
Beskrivning

Patients

Datatyp

boolean

Alias
UMLS CUI [1]
C0030705
1. age <18
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
2. performance status (ecog/who) > 2 (see appendix 2)
Beskrivning

ECOG performance status | WHO performance status scale

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
UMLS CUI [2]
C1298650
3. inability to provide written informed consent
Beskrivning

Informed Consent Unable

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
4. pregnancy
Beskrivning

Pregnancy

Datatyp

boolean

Alias
UMLS CUI [1]
C0032961
5. chronic phase disease
Beskrivning

Chronic Phase of Disease

Datatyp

boolean

Alias
UMLS CUI [1]
C1333047
6. formal refusal of any recommendation of a safe contraception
Beskrivning

Contraceptive methods Refused

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0700589
UMLS CUI [1,2]
C1705116
7. alcohol or drug addiction
Beskrivning

Substance Dependence

Datatyp

boolean

Alias
UMLS CUI [1]
C0038580
8. altered hepatic or renal function as defined by ast/alt or bilirubin > 3 times upper normal limits (unl)
Beskrivning

Liver function altered | Renal function altered | Aspartate aminotransferase increased | Alanine aminotransferase increased | Elevated total bilirubin

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0392747
UMLS CUI [2,1]
C0232804
UMLS CUI [2,2]
C0392747
UMLS CUI [3]
C0151904
UMLS CUI [4]
C0151905
UMLS CUI [5]
C0741494
9. serum creatinine > 265 umol/l or >3.0 mg/dl
Beskrivning

Creatinine measurement, serum

Datatyp

boolean

Alias
UMLS CUI [1]
C0201976
10. any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.
Beskrivning

Disease At risk Patient | Condition At risk Patient | Disease Study Subject Participation Status Ineligibility | Condition Study Subject Participation Status Ineligibility

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0030705
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C1444641
UMLS CUI [2,3]
C0030705
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C2348568
UMLS CUI [3,3]
C1512714
UMLS CUI [4,1]
C0348080
UMLS CUI [4,2]
C2348568
UMLS CUI [4,3]
C1512714
Tillbaka till toppen

Similar models

Eligibility Leukemia NCT00511069

1 Formulär
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00511069
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Age
Item
1. age >/=18 years
boolean
C0001779 (UMLS CUI [1])
Philadelphia positive
Item
2. ph positive
boolean
C0457340 (UMLS CUI [1])
imatinib | Complete Hematologic Response Absent
Item
3. absence of a chr after 3 months on imatinib
boolean
C0935989 (UMLS CUI [1])
C4050175 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
imatinib | Complete Hematologic Response Obtained Previous | Complete Hematologic Response Lost
Item
4. loss of a previously obtained chr on imatinib alone
boolean
C0935989 (UMLS CUI [1])
C4050175 (UMLS CUI [2,1])
C1301820 (UMLS CUI [2,2])
C0205156 (UMLS CUI [2,3])
C4050175 (UMLS CUI [3,1])
C0745777 (UMLS CUI [3,2])
imatinib | Cytogenetic Complete Response Absent
Item
5. absence of a ccgr within 12 months on imatinib alone
boolean
C0935989 (UMLS CUI [1])
C4050364 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
imatinib | Cytogenetic Complete Response Obtained Previous | Cytogenetic Complete Response Lost
Item
6. loss of a previously obtained ccgr on imatinib alone
boolean
C0935989 (UMLS CUI [1])
C4050364 (UMLS CUI [2,1])
C1301820 (UMLS CUI [2,2])
C0205156 (UMLS CUI [2,3])
C4050364 (UMLS CUI [3,1])
C0745777 (UMLS CUI [3,2])
Informed Consent
Item
7. written informed consent
boolean
C0021430 (UMLS CUI [1])
Exclusion Criteria | Chronic phase
Item
exclusion criteria for chronic phase patients :
boolean
C0680251 (UMLS CUI [1])
C0457343 (UMLS CUI [2])
Age
Item
1. age <18
boolean
C0001779 (UMLS CUI [1])
ECOG performance status | WHO performance status scale
Item
2. performance status (ecog/who) > 2 (see appendix 2)
boolean
C1520224 (UMLS CUI [1])
C1298650 (UMLS CUI [2])
Informed Consent Unable
Item
3. inability to provide written informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Pregnancy
Item
4. pregnancy
boolean
C0032961 (UMLS CUI [1])
Accelerated phase | Blastic Phase
Item
5. accelerated or blastic phase
boolean
C0457345 (UMLS CUI [1])
C3899938 (UMLS CUI [2])
Contraceptive methods Refused
Item
6. formal refusal of any recommendation of a safe contraception
boolean
C0700589 (UMLS CUI [1,1])
C1705116 (UMLS CUI [1,2])
Substance Dependence
Item
7. alcohol or drug addiction
boolean
C0038580 (UMLS CUI [1])
Liver function altered | Renal function altered | Aspartate aminotransferase increased | Alanine aminotransferase increased | Elevated total bilirubin
Item
8. altered hepatic or renal function as defined by ast/alt or bilirubin > 3 times upper normal limits (unl)
boolean
C0232741 (UMLS CUI [1,1])
C0392747 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0151904 (UMLS CUI [3])
C0151905 (UMLS CUI [4])
C0741494 (UMLS CUI [5])
Creatinine measurement, serum
Item
9. serum creatinine > 265 umol/l or >3.0 mg/dl
boolean
C0201976 (UMLS CUI [1])
Disease At risk Patient | Condition At risk Patient | Disease Study Subject Participation Status Ineligibility | Condition Study Subject Participation Status Ineligibility
Item
10. any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.
boolean
C0012634 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0030705 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0030705 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C1512714 (UMLS CUI [3,3])
C0348080 (UMLS CUI [4,1])
C2348568 (UMLS CUI [4,2])
C1512714 (UMLS CUI [4,3])
Inclusion criteria | Accelerated phase | Blastic Phase | Philadelphia chromosome-positive acute lymphoblastic leukemia
Item
inclusion criteria for accelerated and blastic phase or acute lymphoblastic leukemia ph+
boolean
C1512693 (UMLS CUI [1])
C0457345 (UMLS CUI [2])
C3899938 (UMLS CUI [3])
C1960397 (UMLS CUI [4])
Patients
Item
patients:
boolean
C0030705 (UMLS CUI [1])
Age
Item
1. age >/=18 years
boolean
C0001779 (UMLS CUI [1])
Philadelphia positive
Item
2. ph positive
boolean
C0457340 (UMLS CUI [1])
imatinib | Hematologic Response Previous | Hematologic Response Lost | Progression Accelerated phase | Progression Blastic Phase
Item
3. loss of a previous hematological response to imatinib alone, with further progression to abp (see section 14 for definitions)
boolean
C0935989 (UMLS CUI [1])
C4054793 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C4054793 (UMLS CUI [3,1])
C0745777 (UMLS CUI [3,2])
C0449258 (UMLS CUI [4,1])
C0457345 (UMLS CUI [4,2])
C0449258 (UMLS CUI [5,1])
C3899938 (UMLS CUI [5,2])
ECOG performance status | WHO performance status scale
Item
4. performance status (ecog/who)
boolean
C1520224 (UMLS CUI [1])
C1298650 (UMLS CUI [2])
Informed Consent
Item
5. written informed consent
boolean
C0021430 (UMLS CUI [1])
Exclusion Criteria | Accelerated phase | Blastic Phase | Philadelphia chromosome-positive acute lymphoblastic leukemia
Item
exclusion criteria for accelerated and blastic phase or acute lymphoblastic leukemia ph+
boolean
C0680251 (UMLS CUI [1])
C0457345 (UMLS CUI [2])
C3899938 (UMLS CUI [3])
C1960397 (UMLS CUI [4])
Patients
Item
patients:
boolean
C0030705 (UMLS CUI [1])
Age
Item
1. age <18
boolean
C0001779 (UMLS CUI [1])
ECOG performance status | WHO performance status scale
Item
2. performance status (ecog/who) > 2 (see appendix 2)
boolean
C1520224 (UMLS CUI [1])
C1298650 (UMLS CUI [2])
Informed Consent Unable
Item
3. inability to provide written informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Pregnancy
Item
4. pregnancy
boolean
C0032961 (UMLS CUI [1])
Chronic Phase of Disease
Item
5. chronic phase disease
boolean
C1333047 (UMLS CUI [1])
Contraceptive methods Refused
Item
6. formal refusal of any recommendation of a safe contraception
boolean
C0700589 (UMLS CUI [1,1])
C1705116 (UMLS CUI [1,2])
Substance Dependence
Item
7. alcohol or drug addiction
boolean
C0038580 (UMLS CUI [1])
Liver function altered | Renal function altered | Aspartate aminotransferase increased | Alanine aminotransferase increased | Elevated total bilirubin
Item
8. altered hepatic or renal function as defined by ast/alt or bilirubin > 3 times upper normal limits (unl)
boolean
C0232741 (UMLS CUI [1,1])
C0392747 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0151904 (UMLS CUI [3])
C0151905 (UMLS CUI [4])
C0741494 (UMLS CUI [5])
Creatinine measurement, serum
Item
9. serum creatinine > 265 umol/l or >3.0 mg/dl
boolean
C0201976 (UMLS CUI [1])
Disease At risk Patient | Condition At risk Patient | Disease Study Subject Participation Status Ineligibility | Condition Study Subject Participation Status Ineligibility
Item
10. any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.
boolean
C0012634 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0030705 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0030705 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C1512714 (UMLS CUI [3,3])
C0348080 (UMLS CUI [4,1])
C2348568 (UMLS CUI [4,2])
C1512714 (UMLS CUI [4,3])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial